期刊
CLINICAL RHEUMATOLOGY
卷 39, 期 9, 页码 2573-2581出版社
SPRINGER LONDON LTD
DOI: 10.1007/s10067-020-05043-1
关键词
CXCL13; Predictive biomarker; Response; Rheumatoid arthritis; sICAM-1; TNF inhibitor
类别
资金
- Peking University Clinical Research Program [PUCRP201305]
- National Natural Science Foundation of China [81771740, 81971524]
Background Tumor necrosis factor-alpha (TNF alpha) inhibitors (TNFi) have greatly improved the prognosis of RA and become the first therapeutic option for patients who failed the conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) therapy, but not all these patients respond well to TNFi. So far, there has been no definite biomarker to predict the response to TNFi yet. Methods Sixty rheumatoid arthritis (RA) patients with disease duration more than 6 months and at least low disease activity defined by DAS28-CRP > 3.2 although after csDMARDs (including MTX and/or leflunomide) treatment for more than 3 months were included. They were further treated with TNF alpha receptor Fc fusion protein and MTX 10 mg per week for 12 weeks. Soluble ICAM-1 (sICAM-1) and CXCL13 concentrations in sera from 60 RA patients and 20 healthy controls were tested by ELISA right before and at the end of 12 weeks of TNFi therapy. The correlation between sICAM-1 and CXCL13 with disease activity and their predictive values for TNFi response were analyzed. Results The mean age of the 60 patients was 54.8 +/- 11.6 years. Serum sICAM-1 and CXCL13 concentrations were higher in RA patients than heathy controls, higher in seropositive RA patients than in seronegative ones, and higher in RA patients with higher disease activity. Serum sICAM-1 and CXCL13 levels were decreased after TNFi therapy, especially in good responders. Baseline sICAM-1 concentration was independently associated with the EULAR response (p = 0.033, OR = 1.014, 95% CI = 1.003-1.026). The sICAM-1(high)/CXCL13(high) patients had the highest response rate, which was significantly higher than the sICAM-1(low)/CXCL13(low) group (OR = 8.143, 95% CI = 1.040-75.482, p = 0.045). Conclusion sICAM-1 and CXCL13 are elevated in RA patients and correlated with disease activity. sICAM-1 is an independent predictor of TNFi response in csDMARDs refractory RA patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据